Colleen F. Reitan

Board Director

Director

US·SEC (Form 4)

Myriad Genetics Inc Alnylam Pharmaceuticals, Inc.

Cumul. flow

Total declarations

Companies

▲ Purchases (1 ops.)

€8,260

▼ Sales (1 ops.)

€1.2M

Latest filing published 22 May 2026 for ALNYLAM PHARMACEUTICALS, INC.. Read the official filing

Filing timeline

BuySale

Colleen F. Reitan

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

ALNYLAM PHARMACEUTICALS, INC. 1 purchase · last 12 May 2025

Since each purchase

Alnylam Pharmaceuticals, Inc.
Filed 12 May 2025 · 524 days ago · €8,260
+9.2%
Entry US$266.86 · Close at T+365 US$291.48

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Colleen F. Reitan: trading record in brief

Filings by Colleen F. Reitan span 2 companies, the busiest being Myriad Genetics Inc and Alnylam Pharmaceuticals, Inc. Between 3 June 2021 and 20 May 2026, the trades on record add up to 9 filings.

Market trades split into 1 purchase (€8,260) and 1 sale (€1.2M). Sales outweigh purchases by €1.2M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 6 share grants and 1 option exercise.

Most recently, on 22 May 2026, the filings show a share grant in Alnylam Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 524 days ago, on 12 May 2025. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.